2026 ASCO Genitourinary Cancers Symposium: Focus on Prostate Cancer

Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.

Real-world treatment with relugolix maintained QOL outcomes and had a manageable safety profile in patients with advanced prostate cancer.

PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

Lutetium Lu 177 vipivotide tetraxetan was active after treatment with sipuleucel-T in real-world mCRPC.

PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC.

PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

Short-course darolutamide boosted PSMA expression in some high-risk localized prostate cancer, supporting improved PSMA PET imaging strategies.